3,363 reports of this reaction
1.4% of all CETIIRIZINE reports
#14 most reported adverse reaction
JOINT SWELLING is the #14 most commonly reported adverse reaction for CETIIRIZINE, manufactured by Amneal Pharmaceuticals LLC. There are 3,363 FDA adverse event reports linking CETIIRIZINE to JOINT SWELLING. This represents approximately 1.4% of all 233,494 adverse event reports for this drug.
Patients taking CETIIRIZINE who experience joint swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT SWELLING is a less commonly reported adverse event for CETIIRIZINE, but still significant enough to appear in the safety profile.
In addition to joint swelling, the following adverse reactions have been reported for CETIIRIZINE:
The following drugs have also been linked to joint swelling in FDA adverse event reports:
JOINT SWELLING has been reported as an adverse event in 3,363 FDA reports for CETIIRIZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT SWELLING accounts for approximately 1.4% of all adverse event reports for CETIIRIZINE, making it a notable side effect.
If you experience joint swelling while taking CETIIRIZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.